🇺🇸 FDA
Pipeline program

Saline (0.9%, sterile, for infusion)

2025-I2M-C&T-B-090B

Phase 3 small_molecule active

Quick answer

Saline (0.9%, sterile, for infusion) for Pneumocystis Jiroveci Pneumonia is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Pneumocystis Jiroveci Pneumonia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials